Free Trial

4basebio (LON:4BB) Trading Down 2.1% - Here's What Happened

4basebio logo with Medical background

4basebio PLC (LON:4BB - Get Free Report)'s share price was down 2.1% during mid-day trading on Thursday . The company traded as low as GBX 1,185 ($14.72) and last traded at GBX 1,185 ($14.72). Approximately 3,034 shares traded hands during mid-day trading, a decline of 31% from the average daily volume of 4,379 shares. The stock had previously closed at GBX 1,210 ($15.03).

4basebio Stock Performance

The company has a current ratio of 2.73, a quick ratio of 3.52 and a debt-to-equity ratio of 201.47. The stock has a market capitalization of £149.88 million, a price-to-earnings ratio of -1,500.00 and a beta of 1.09. The firm's fifty day moving average price is GBX 1,247.97 and its 200 day moving average price is GBX 1,375.28.

Insiders Place Their Bets

In other 4basebio news, insider Heikki Lanckriet acquired 46,500 shares of the stock in a transaction dated Friday, November 15th. The stock was acquired at an average price of GBX 1,325 ($16.46) per share, with a total value of £616,125 ($765,372.67). 68.44% of the stock is owned by insiders.

About 4basebio

(Get Free Report)

4basebio is a specialist life sciences group focused on supplying therapeutic synthetic DNA for gene therapies and gene-based vaccines and providing solutions for effective and safe delivery of DNA/RNA based products to patients. Our focus is the development of high quality, GMP grade synthetic DNA as well as non-viral nanoparticles which can efficiently and safely deliver fully functional genes to patients.

Featured Stories

Should You Invest $1,000 in 4basebio Right Now?

Before you consider 4basebio, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and 4basebio wasn't on the list.

While 4basebio currently has a "Hold" rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

7 AI Stocks to Invest In: An Introduction to AI Investing For Self-Directed Investors Cover

As the AI market heats up, investors who have a vision for artificial intelligence have the potential to see real returns. Learn about the industry as a whole as well as seven companies that are getting work done with the power of AI.

Get This Free Report
Like this article? Share it with a colleague.

Featured Articles and Offers

7 Large-Cap Stocks Headed for Strong, Steady Gains in 2025

7 Large-Cap Stocks Headed for Strong, Steady Gains in 2025

While 2025 may not deliver massive returns, so MarketBeat analyst Chris Markoch shares his list of seven stocks primed for consistent performance.

Related Videos

The Real Reason Tesla Stock Is Soaring – and Why Tech Expert Says It Won’t Stop
Small Caps, Financials & Bitcoin Lead the Rising Bull Market: Chris Rowe’s Top Picks
Massive Market Moves Following Trump Win: Tesla, JP Morgan, & Bitcoin Soar

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines